Pharmavise Consulting Corporation – Trademark Portfolio
Entity Type: 03
Pharmavise Consulting Corporation holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include SYMVOS. The owner is based in Coral Springs, FL.
Suite 100
3301 N. University Drive
Coral Springs, FL 33065
Showing of trademarks Trademarks
Trademark Classifications
Pharmavise Consulting Corporation's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Pharmavise Consulting Corporation have?
Pharmavise Consulting Corporation has 3 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending, 1 abandoned.
What trademark classes does Pharmavise Consulting Corporation file in?
Pharmavise Consulting Corporation files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 35 (Advertising & Business). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Pharmavise Consulting Corporation's most well-known trademarks?
Pharmavise Consulting Corporation's registered trademark portfolio includes well-known marks such as SYMVOS. These are among 1 currently registered trademark in the portfolio.
What is Pharmavise Consulting Corporation's trademark registration success rate?
Pharmavise Consulting Corporation has a 50% trademark registration rate, with 1 out of 2 resolved applications resulting in successful registration. Currently, 1 application is pending review.